APO Research
Talk to an analyst

APO RESEARCH · REPORT

Brain and Central Nervous System Cancer Treatments

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Brain and Central Nervous System Cancer Treatments Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025191 pages

Choose your research edition.

Industry ResearchBrain and Central Nervous System Cancer Treatments Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Brain and Central Nervous System Cancer Treatments Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Brain and Central Nervous System Cancer Treatments Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Brain and Central Nervous System Cancer Treatments Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Brain and Central Nervous System Cancer Treatments Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Brain and Central Nervous System Cancer Treatments market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Brain and Central Nervous System Cancer Treatments include Teva, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, Bayer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Brain and Central Nervous System Cancer Treatments market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Brain and Central Nervous System Cancer Treatments and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Brain and Central Nervous System Cancer Treatments sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Brain and Central Nervous System Cancer Treatments market size, projected growth trends, production technologies, key applications, and end-use industries.

Brain and Central Nervous System Cancer Treatments Segment by Company

Teva

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Roche

Pfizer

Bayer

AbbVie

Takeda

Otsuka

Merck KGaA

Ipsen

Gilead Sciences

Eli Lilly

Eisai

Celgene

Bristol-Myers Squibb

Biogen Idec

AstraZeneca

Astellas

Amgen

Brain and Central Nervous System Cancer Treatments Segment by Type

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Chemotherapy

Targeted Therapy

Others

Brain and Central Nervous System Cancer Treatments Segment by Application

Brain Cancer

Spinal Cord Cancer

Others

Brain and Central Nervous System Cancer Treatments Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brain and Central Nervous System Cancer Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Brain and Central Nervous System Cancer Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brain and Central Nervous System Cancer Treatments.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Brain and Central Nervous System Cancer Treatments market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Brain and Central Nervous System Cancer Treatments manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Brain and Central Nervous System Cancer Treatments in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Brain and Central Nervous System Cancer Treatments in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Brain and Central Nervous System Cancer Treatments Industry Trends Table 2. Brain and Central Nervous System Cancer Treatments Industry Drivers Table 3. Brain and Central Nervous System Cancer Treatments Industry Opportunities and Challenges Table 4. Brain and Central Nervous System Cancer Treatments Industry Restraints Table 5. Global Brain and Central Nervous System Cancer Treatments Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Brain and Central Nervous System Cancer Treatments Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Manufacturers Table 9. Global Brain and Central Nervous System Cancer Treatments Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Brain and Central Nervous System Cancer Treatments Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Brain and Central Nervous System Cancer Treatments Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Brain and Central Nervous System Cancer Treatments Manufacturers, Product Type & Application Table 13. Global Brain and Central Nervous System Cancer Treatments Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Brain and Central Nervous System Cancer Treatments by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Immunotherapy (Biologic Therapy) Table 17. Major Manufacturers of Hormonal Therapy Table 18. Major Manufacturers of Chemotherapy Table 19. Major Manufacturers of Targeted Therapy Table 20. Major Manufacturers of Others Table 21. Global Brain and Central Nervous System Cancer Treatments Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021-2026) & (K Units) Table 23. Global Brain and Central Nervous System Cancer Treatments Sales by Type (2027-2032) & (K Units) Table 24. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021-2026) Table 25. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2027-2032) Table 26. Global Brain and Central Nervous System Cancer Treatments Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021-2026) & (K Units) Table 28. Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2027-2032) & (K Units) Table 29. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021-2026) Table 30. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Brain Cancer Table 32. Major Manufacturers of Spinal Cord Cancer Table 33. Major Manufacturers of Others Table 34. Global Brain and Central Nervous System Cancer Treatments Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021-2026) & (K Units) Table 36. Global Brain and Central Nervous System Cancer Treatments Sales by Application (2027-2032) & (K Units) Table 37. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021-2026) Table 38. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2027-2032) Table 39. Global Brain and Central Nervous System Cancer Treatments Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021-2026) & (K Units) Table 41. Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2027-2032) & (K Units) Table 42. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021-2026) Table 43. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2027-2032) Table 44. Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Brain and Central Nervous System Cancer Treatments Sales by Region (2021-2026) & (K Units) Table 46. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2021-2026) Table 47. Global Brain and Central Nervous System Cancer Treatments Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Brain and Central Nervous System Cancer Treatments Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 51. North America Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 52. Europe Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 54. Europe Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 61. Global Brain and Central Nervous System Cancer Treatments Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Brain and Central Nervous System Cancer Treatments Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Brain and Central Nervous System Cancer Treatments Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2021-2026) Table 65. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2027-2032) Table 66. Teva Company Information Table 67. Teva Business Overview Table 68. Teva Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Teva Brain and Central Nervous System Cancer Treatments Product Portfolio Table 70. Teva Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Sanofi Brain and Central Nervous System Cancer Treatments Product Portfolio Table 75. Sanofi Recent Development Table 76. Johnson & Johnson Company Information Table 77. Johnson & Johnson Business Overview Table 78. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product Portfolio Table 80. Johnson & Johnson Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novartis Brain and Central Nervous System Cancer Treatments Product Portfolio Table 85. Novartis Recent Development Table 86. Merck & Co. Company Information Table 87. Merck & Co. Business Overview Table 88. Merck & Co. Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Merck & Co. Brain and Central Nervous System Cancer Treatments Product Portfolio Table 90. Merck & Co. Recent Development Table 91. Roche Company Information Table 92. Roche Business Overview Table 93. Roche Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Roche Brain and Central Nervous System Cancer Treatments Product Portfolio Table 95. Roche Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Pfizer Brain and Central Nervous System Cancer Treatments Product Portfolio Table 100. Pfizer Recent Development Table 101. Bayer Company Information Table 102. Bayer Business Overview Table 103. Bayer Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Bayer Brain and Central Nervous System Cancer Treatments Product Portfolio Table 105. Bayer Recent Development Table 106. AbbVie Company Information Table 107. AbbVie Business Overview Table 108. AbbVie Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. AbbVie Brain and Central Nervous System Cancer Treatments Product Portfolio Table 110. AbbVie Recent Development Table 111. Takeda Company Information Table 112. Takeda Business Overview Table 113. Takeda Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Takeda Brain and Central Nervous System Cancer Treatments Product Portfolio Table 115. Takeda Recent Development Table 116. Otsuka Company Information Table 117. Otsuka Business Overview Table 118. Otsuka Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Otsuka Brain and Central Nervous System Cancer Treatments Product Portfolio Table 120. Otsuka Recent Development Table 121. Merck KGaA Company Information Table 122. Merck KGaA Business Overview Table 123. Merck KGaA Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Merck KGaA Brain and Central Nervous System Cancer Treatments Product Portfolio Table 125. Merck KGaA Recent Development Table 126. Ipsen Company Information Table 127. Ipsen Business Overview Table 128. Ipsen Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Ipsen Brain and Central Nervous System Cancer Treatments Product Portfolio Table 130. Ipsen Recent Development Table 131. Gilead Sciences Company Information Table 132. Gilead Sciences Business Overview Table 133. Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Gilead Sciences Brain and Central Nervous System Cancer Treatments Product Portfolio Table 135. Gilead Sciences Recent Development Table 136. Eli Lilly Company Information Table 137. Eli Lilly Business Overview Table 138. Eli Lilly Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Eli Lilly Brain and Central Nervous System Cancer Treatments Product Portfolio Table 140. Eli Lilly Recent Development Table 141. Eisai Company Information Table 142. Eisai Business Overview Table 143. Eisai Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Eisai Brain and Central Nervous System Cancer Treatments Product Portfolio Table 145. Eisai Recent Development Table 146. Celgene Company Information Table 147. Celgene Business Overview Table 148. Celgene Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Celgene Brain and Central Nervous System Cancer Treatments Product Portfolio Table 150. Celgene Recent Development Table 151. Bristol-Myers Squibb Company Information Table 152. Bristol-Myers Squibb Business Overview Table 153. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product Portfolio Table 155. Bristol-Myers Squibb Recent Development Table 156. Biogen Idec Company Information Table 157. Biogen Idec Business Overview Table 158. Biogen Idec Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Biogen Idec Brain and Central Nervous System Cancer Treatments Product Portfolio Table 160. Biogen Idec Recent Development Table 161. AstraZeneca Company Information Table 162. AstraZeneca Business Overview Table 163. AstraZeneca Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. AstraZeneca Brain and Central Nervous System Cancer Treatments Product Portfolio Table 165. AstraZeneca Recent Development Table 166. Astellas Company Information Table 167. Astellas Business Overview Table 168. Astellas Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. Astellas Brain and Central Nervous System Cancer Treatments Product Portfolio Table 170. Astellas Recent Development Table 171. Amgen Company Information Table 172. Amgen Business Overview Table 173. Amgen Brain and Central Nervous System Cancer Treatments Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. Amgen Brain and Central Nervous System Cancer Treatments Product Portfolio Table 175. Amgen Recent Development Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Brain and Central Nervous System Cancer Treatments Distributors List Table 179. Brain and Central Nervous System Cancer Treatments Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Brain and Central Nervous System Cancer Treatments Product Image Figure 2. Global Brain and Central Nervous System Cancer Treatments Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Brain and Central Nervous System Cancer Treatments Market Size (2021-2032) & (US$ Million) Figure 4. Global Brain and Central Nervous System Cancer Treatments Sales (2021-2032) & (K Units) Figure 5. Global Brain and Central Nervous System Cancer Treatments Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Brain and Central Nervous System Cancer Treatments Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Immunotherapy (Biologic Therapy) Image Figure 9. Hormonal Therapy Image Figure 10. Chemotherapy Image Figure 11. Targeted Therapy Image Figure 12. Others Image Figure 13. Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Brain and Central Nervous System Cancer Treatments Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021-2032) Figure 16. Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021-2032) Figure 19. Brain Cancer Image Figure 20. Spinal Cord Cancer Image Figure 21. Others Image Figure 22. Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Brain and Central Nervous System Cancer Treatments Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021-2032) Figure 25. Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021-2032) Figure 28. North America Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 30. U.S. Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 35. Germany Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 42. China Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 50. Brazil Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Brain and Central Nervous System Cancer Treatments Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Brain and Central Nervous System Cancer Treatments Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Brain and Central Nervous System Cancer Treatments Revenue (2021-2032) & (US$ Million) Figure 61. North America Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Brain and Central Nervous System Cancer Treatments Revenue (2021-2032) & (US$ Million) Figure 63. Europe Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Brain and Central Nervous System Cancer Treatments Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Brain and Central Nervous System Cancer Treatments Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Brain and Central Nervous System Cancer Treatments Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Others
Applications
  • Brain Cancer
  • Spinal Cord Cancer
  • Others
Companies covered
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Roche
  • Pfizer
  • Bayer
  • AbbVie
  • Takeda
  • Otsuka
  • Merck KGaA
  • Ipsen
  • Gilead Sciences
  • Eli Lilly
  • Eisai
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • AstraZeneca
  • Astellas
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Brain and Central Nervous System Cancer Treatments Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Brain and Central Nervous System Cancer Treatments Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Brain and Central Nervous System Cancer Treatments Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Brain and Central Nervous System Cancer Treatments Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Brain and Central Nervous System Cancer Treatments Market Dynamics
  1. 2.1 Brain and Central Nervous System Cancer Treatments Industry Trends
  2. 2.2 Brain and Central Nervous System Cancer Treatments Industry Drivers
  3. 2.3 Brain and Central Nervous System Cancer Treatments Industry Opportunities and Challenges
  4. 2.4 Brain and Central Nervous System Cancer Treatments Industry Restraints
3 Brain and Central Nervous System Cancer Treatments Market by Manufacturers
  1. 3.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Brain and Central Nervous System Cancer Treatments Sales by Manufacturers (2021-2026)
  3. 3.3 Global Brain and Central Nervous System Cancer Treatments Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Brain and Central Nervous System Cancer Treatments Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Brain and Central Nervous System Cancer Treatments Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Brain and Central Nervous System Cancer Treatments Manufacturers, Product Type & Application
  7. 3.7 Global Brain and Central Nervous System Cancer Treatments Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Brain and Central Nervous System Cancer Treatments Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Brain and Central Nervous System Cancer Treatments Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Brain and Central Nervous System Cancer Treatments Tier 1, Tier 2, and Tier 3
4 Brain and Central Nervous System Cancer Treatments Market by Type
  1. 4.1 Brain and Central Nervous System Cancer Treatments Type Introduction
  2. 4.1.1 Immunotherapy (Biologic Therapy)
  3. 4.1.2 Hormonal Therapy
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Targeted Therapy
  6. 4.1.5 Others
  7. 4.2 Global Brain and Central Nervous System Cancer Treatments Sales by Type
  8. 4.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021-2032)
  10. 4.2.3 Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021-2032)
  11. 4.3 Global Brain and Central Nervous System Cancer Treatments Revenue by Type
  12. 4.3.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021-2032)
  14. 4.3.3 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021-2032)
5 Brain and Central Nervous System Cancer Treatments Market by Application
  1. 5.1 Brain and Central Nervous System Cancer Treatments Application Introduction
  2. 5.1.1 Brain Cancer
  3. 5.1.2 Spinal Cord Cancer
  4. 5.1.3 Others
  5. 5.2 Global Brain and Central Nervous System Cancer Treatments Sales by Application
  6. 5.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021-2032)
  8. 5.2.3 Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021-2032)
  9. 5.3 Global Brain and Central Nervous System Cancer Treatments Revenue by Application
  10. 5.3.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021-2032)
  12. 5.3.3 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021-2032)
6 Global Brain and Central Nervous System Cancer Treatments Sales by Region
  1. 6.1 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Brain and Central Nervous System Cancer Treatments Sales by Region (2021-2032)
  3. 6.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Region (2021-2026)
  4. 6.2.2 Global Brain and Central Nervous System Cancer Treatments Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Brain and Central Nervous System Cancer Treatments Revenue by Region
  1. 7.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Region
  2. 7.1.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Region (2021-2026)
  4. 7.1.3 Global Brain and Central Nervous System Cancer Treatments Revenue by Region (2027-2032)
  5. 7.1.4 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Brain and Central Nervous System Cancer Treatments Revenue (2021-2032)
  8. 7.2.2 North America Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Brain and Central Nervous System Cancer Treatments Revenue (2021-2032)
  11. 7.3.2 Europe Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Brain and Central Nervous System Cancer Treatments Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Brain and Central Nervous System Cancer Treatments Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Brain and Central Nervous System Cancer Treatments Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Brain and Central Nervous System Cancer Treatments Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck & Co.
  26. 8.5.1 Merck & Co. Company Information
  27. 8.5.2 Merck & Co. Business Overview
  28. 8.5.3 Merck & Co. Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co. Brain and Central Nervous System Cancer Treatments Product Portfolio
  30. 8.5.5 Merck & Co. Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Brain and Central Nervous System Cancer Treatments Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Brain and Central Nervous System Cancer Treatments Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Brain and Central Nervous System Cancer Treatments Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Brain and Central Nervous System Cancer Treatments Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 Takeda
  56. 8.10.1 Takeda Company Information
  57. 8.10.2 Takeda Business Overview
  58. 8.10.3 Takeda Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takeda Brain and Central Nervous System Cancer Treatments Product Portfolio
  60. 8.10.5 Takeda Recent Developments
  61. 8.11 Otsuka
  62. 8.11.1 Otsuka Company Information
  63. 8.11.2 Otsuka Business Overview
  64. 8.11.3 Otsuka Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Otsuka Brain and Central Nervous System Cancer Treatments Product Portfolio
  66. 8.11.5 Otsuka Recent Developments
  67. 8.12 Merck KGaA
  68. 8.12.1 Merck KGaA Company Information
  69. 8.12.2 Merck KGaA Business Overview
  70. 8.12.3 Merck KGaA Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck KGaA Brain and Central Nervous System Cancer Treatments Product Portfolio
  72. 8.12.5 Merck KGaA Recent Developments
  73. 8.13 Ipsen
  74. 8.13.1 Ipsen Company Information
  75. 8.13.2 Ipsen Business Overview
  76. 8.13.3 Ipsen Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ipsen Brain and Central Nervous System Cancer Treatments Product Portfolio
  78. 8.13.5 Ipsen Recent Developments
  79. 8.14 Gilead Sciences
  80. 8.14.1 Gilead Sciences Company Information
  81. 8.14.2 Gilead Sciences Business Overview
  82. 8.14.3 Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Gilead Sciences Brain and Central Nervous System Cancer Treatments Product Portfolio
  84. 8.14.5 Gilead Sciences Recent Developments
  85. 8.15 Eli Lilly
  86. 8.15.1 Eli Lilly Company Information
  87. 8.15.2 Eli Lilly Business Overview
  88. 8.15.3 Eli Lilly Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Eli Lilly Brain and Central Nervous System Cancer Treatments Product Portfolio
  90. 8.15.5 Eli Lilly Recent Developments
  91. 8.16 Eisai
  92. 8.16.1 Eisai Company Information
  93. 8.16.2 Eisai Business Overview
  94. 8.16.3 Eisai Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Eisai Brain and Central Nervous System Cancer Treatments Product Portfolio
  96. 8.16.5 Eisai Recent Developments
  97. 8.17 Celgene
  98. 8.17.1 Celgene Company Information
  99. 8.17.2 Celgene Business Overview
  100. 8.17.3 Celgene Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Celgene Brain and Central Nervous System Cancer Treatments Product Portfolio
  102. 8.17.5 Celgene Recent Developments
  103. 8.18 Bristol-Myers Squibb
  104. 8.18.1 Bristol-Myers Squibb Company Information
  105. 8.18.2 Bristol-Myers Squibb Business Overview
  106. 8.18.3 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product Portfolio
  108. 8.18.5 Bristol-Myers Squibb Recent Developments
  109. 8.19 Biogen Idec
  110. 8.19.1 Biogen Idec Company Information
  111. 8.19.2 Biogen Idec Business Overview
  112. 8.19.3 Biogen Idec Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Biogen Idec Brain and Central Nervous System Cancer Treatments Product Portfolio
  114. 8.19.5 Biogen Idec Recent Developments
  115. 8.20 AstraZeneca
  116. 8.20.1 AstraZeneca Company Information
  117. 8.20.2 AstraZeneca Business Overview
  118. 8.20.3 AstraZeneca Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 AstraZeneca Brain and Central Nervous System Cancer Treatments Product Portfolio
  120. 8.20.5 AstraZeneca Recent Developments
  121. 8.21 Astellas
  122. 8.21.1 Astellas Company Information
  123. 8.21.2 Astellas Business Overview
  124. 8.21.3 Astellas Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Astellas Brain and Central Nervous System Cancer Treatments Product Portfolio
  126. 8.21.5 Astellas Recent Developments
  127. 8.22 Amgen
  128. 8.22.1 Amgen Company Information
  129. 8.22.2 Amgen Business Overview
  130. 8.22.3 Amgen Brain and Central Nervous System Cancer Treatments Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Amgen Brain and Central Nervous System Cancer Treatments Product Portfolio
  132. 8.22.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Brain and Central Nervous System Cancer Treatments Value Chain Analysis
  2. 9.1.1 Brain and Central Nervous System Cancer Treatments Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Brain and Central Nervous System Cancer Treatments Production Mode & Process
  6. 9.2 Brain and Central Nervous System Cancer Treatments Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Brain and Central Nervous System Cancer Treatments Distributors
  9. 9.2.3 Brain and Central Nervous System Cancer Treatments Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst